PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:
AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy
Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO
Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Date and Time: October 19, 2024, 6:00 - 8:15pm ET
Location: Boston, MA
ISV Congress 2024
Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 22, 2024, 4:20pm KST
Location: Seoul, Korea
Fall Voice
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 25 – October 26, 2024
Location: Phoenix, AZ
World Vaccine Congress Europe
Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO
Track: Pre-Congress Workshop on Platform Technologies
Date and Time: October 28, 2024, 10:00am CET
Location: Barcelona, Spain
Abstracts from these conferences will be made available on INOVIO's website following each presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
SOURCE INOVIO Pharmaceuticals, Inc.